ACRV
Acrivon Therapeutics, Inc.
Next earnings Aug 11, 2026 · consensus $-0.52 EPS
Last earnings +1.6% on 2026-05-13
$1.68
▲ +6.33%$1.68▲ +40.00%
over 1Y
L $1.20EODHDH $3.01
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.3%
1W+6.3%
1M+1.2%
3M+26.3%
YTD-31.7%
1Y+40.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity 0.15x).
Return on equity -69.2% · latest
Acrivon Therapeutics, Inc. shows limited reported revenue, and -69.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$16.2M | -$32.7M | -$67.1M | -$89.2M | -$84.1M |
| Net income | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| Diluted EPS | -$9.32 | -$7.56 | -$2.74 | -$2.38 | -$2.02 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$23.6M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-119.7%
FCF yield-100.4%
Quality & risk
ROIC (est.)-59.1%
Free cash flow-$65.3M
Total debt—
Net cash$41.5M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+23.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-03-02). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗8-KPeriod ending 2026-06-172026-06-17open ↗4Period ending 2026-05-212026-05-26open ↗DEFA14AFiling2026-05-22open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗
Frequently asked
- Is Acrivon Therapeutics, Inc. (ACRV) a buy?
- ACRV currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.15x).
- What is Acrivon Therapeutics, Inc.'s quality score?
- ACRV scores 49.102564102564095/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001781174, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 7:02:49 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.